Finland - finsk - Fimea (Suomen lääkevirasto)

desitin arzneimittel gmbh - zolpidemi tartras - tabletti, kalvopäällysteinen - 5 mg - tsolpideemi

Finland - finsk - Fimea (Suomen lääkevirasto)

desitin arzneimittel gmbh - zolpidemi tartras - tabletti, kalvopäällysteinen - 10 mg - tsolpideemi

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

herbal science sdn. bhd. - semen plantaginis; rhizoma rhei; radix ledebouriellae; herba taraxaci; herba andrographitis -

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

desitin arzneimittel gmbh - zolpidemtartrat - filmdragerad tablett - 10 mg - zolpidemtartrat 10 mg aktiv substans; laktosmonohydrat hjälpämne - zolpidem

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

desitin arzneimittel gmbh - zolpidemtartrat - filmdragerad tablett - 5 mg - zolpidemtartrat 5 mg aktiv substans; laktosmonohydrat hjälpämne - zolpidem

Kirgisistan - russisk - Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Купер Фарма Лимитед - Азитромицин - суспензия для приема внутрь - 200 мг/5 мл 15 мл

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 250 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ]. these recommendations are based on either drug interaction studies or observed clinical toxicities. coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5’-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy category b reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exp

USA - engelsk - NLM (National Library of Medicine)

aurobindo pharma limited - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 125 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ] . didanosine delayed-release capsules are contraindicated when coadministered with the following medications: - stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [see warnings and precautions (5.1, 5.2, 5.3, 5.5)] . - allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. - ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy exposure registry there is a preg

USA - engelsk - NLM (National Library of Medicine)

state of florida doh central pharmacy - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 250 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ]. these recommendations are based on either drug interaction studies or observed clinical toxicities. coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5’-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy category b reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exp

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios aurobindo, s.l.u. - didanosina - excipientes: carboximetilalmidon sodico,carmelosa sodica,laurilsulfato de sodio,laurilsulfato de sodio,laurilsulfato de sodio,propilenglicol,potasio, hidroxido de - antivirales de acciÓn directa - nucleosidos y nucleotidos inhibidores de la transcriptasa inversa - didanosina